These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29117486)

  • 1. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
    Stone RM; Larson RA; Döhner H
    N Engl J Med; 2017 Nov; 377(19):1903. PubMed ID: 29117486
    [No Abstract]   [Full Text] [Related]  

  • 2. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research Progress on Treating Acute Myeloid Leukemia by Midostaurin].
    Wang YY; Sun WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1780-4. PubMed ID: 26708910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
    Sahoo RK; Kumar L
    N Engl J Med; 2017 Nov; 377(19):1901-2. PubMed ID: 29120133
    [No Abstract]   [Full Text] [Related]  

  • 6. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
    Eskazan AE
    N Engl J Med; 2017 Nov; 377(19):1901. PubMed ID: 29120132
    [No Abstract]   [Full Text] [Related]  

  • 7. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midostaurin in FLT3-mutated acute myeloid leukaemia.
    Das M
    Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
    [No Abstract]   [Full Text] [Related]  

  • 10. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
    Tvedt TH; Nepstad I; Bruserud Ø
    Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
    Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin + Chemo Ups AML Survival.
    Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin in acute myeloid leukaemia with a
    Sharma A; Bakhshi S
    Natl Med J India; 2018; 31(5):288-290. PubMed ID: 31267996
    [No Abstract]   [Full Text] [Related]  

  • 16. Midostaurin Gets FDA Nod for AML.
    Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin: First Global Approval.
    Kim ES
    Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.
    Lipka DB; Wagner MC; Dziadosz M; Fischer T
    Leukemia; 2016 Oct; 30(10):2090-2093. PubMed ID: 27137475
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.
    Zwaan CM; Söderhäll S; Brethon B; Luciani M; Rizzari C; Stam RW; Besse E; Dutreix C; Fagioli F; Ho PA; Dufour C; Pieters R
    Br J Haematol; 2019 May; 185(3):623-627. PubMed ID: 30203832
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
    Strati P; Kantarjian H; Ravandi F; Nazha A; Borthakur G; Daver N; Kadia T; Estrov Z; Garcia-Manero G; Konopleva M; Rajkhowa T; Durand M; Andreeff M; Levis M; Cortes J
    Am J Hematol; 2015 Apr; 90(4):276-81. PubMed ID: 25530214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.